Gabrielle Sulzberger - Eli Lilly Independent Director
| LLY Stock | USD 864.90 27.33 3.26% |
Director
Gabrielle Sulzberger is Independent Director of Eli Lilly and since 2021.
| Age | 60 |
| Tenure | 4 years |
| Address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has Return on Asset of 0.1533 % which means that on every $100 spent on assets, it made $0.1533 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8426 %, implying that it generated $0.8426 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.78 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 48.3 B in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 3 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Argeris Karabelas | Bausch Health Companies | 66 | |
| Russel Robertson | Bausch Health Companies | 72 | |
| Heather Mason | Assertio Therapeutics | 64 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Michel Orsinger | Takeda Pharmaceutical Co | 62 | |
| Dawn Allen | Haleon plc | 57 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Perry Nisen | Teva Pharma Industries | 64 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Faysal Kalmoua | Alvotech | 49 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Amy Wechsler | Bausch Health Companies | 50 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Rosemary Crane | Teva Pharma Industries | 60 | |
| Robert Power | Bausch Health Companies | 63 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Nechemia Peres | Teva Pharma Industries | 61 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| Koji Hatsukawa | Takeda Pharmaceutical Co | 68 | |
Management Performance
| Return On Equity | 0.84 | ||||
| Return On Asset | 0.15 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sara Smith, Director Relations | ||
| Jamere Jackson, Independent Director | ||
| Johna Norton, Senior Vice President - Global Quality | ||
| Juan Luciano, Lead Independent Director | ||
| J Fyrwald, Independent Director | ||
| Jeffrey MD, Vice Development | ||
| Andrew Adams, Vice Leader | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
| Mark MD, VicePresident Development | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA | ||
| Lucas Montarce, Executive CFO | ||
| Darin Moody, Dry Ingredient | ||
| Karen Walker, Independent Director | ||
| Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines | ||
| Bronwen Mantlo, Deputy VP | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Independent Director | ||
| Gordon Brooks, Controller VP | ||
| Anat JD, General VP | ||
| Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
| Kevin Hern, Vice Relations | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories | ||
| Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations | ||
| Donald Zakrowski, Senior Officer | ||
| Carolyn Bertozzi, Independent Director | ||
| Mr Heath, Group Laboratories | ||
| David MD, Chief Officer | ||
| Kathi Seifert, Independent Director | ||
| Eric Dozier, Executive Diversity | ||
| James Croaning, Global Diabetes | ||
| Joshua Smiley, Chief Financial Officer, Senior Vice President | ||
| Anat Hakim, Senior Vice President, General Counsel, Secretary | ||
| Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | ||
| Jim Greffet, Head Strategy | ||
| Gabrielle Sulzberger, Independent Director | ||
| Anat Ashkenazi, Chief Financial Officer, Senior Vice President | ||
| Kim Macko, Senior Transformation | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| William Kaelin, Independent Director | ||
| John Sims, Senior Neurodegeneration | ||
| Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | ||
| Kimberly Johnson, Independent Director | ||
| Diogo Rau, Senior Vice President Chief Information and Digital Officer | ||
| Aarti Shah, Senior Vice President - Chief Information and Digital Officer | ||
| Jackson Tai, Independent Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Michael Mason, Senior Vice President and President Lilly Diabetes | ||
| Winselow Tucker, Senior Loxo |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.84 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 782.5 B | ||||
| Shares Outstanding | 898.17 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 83.56 % | ||||
| Number Of Shares Shorted | 7.24 M | ||||
| Price To Earning | 54.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.